How to Measure VRET Effectiveness in Your Practice

Why Measure, and Why Measure Well

A psychologist in private practice can treat a patient effectively without ever administering a questionnaire. Clinical judgment, the structured interview, and observed progress are enough to make treatment decisions in most cases.

But measuring with validated instruments provides four things that clinical judgment alone does not. Comparability: your baseline symptomatology against published cohorts and against your own prior caseload. Traceability: objective scores at specific points in time that document progress. Communication: a shared language with the referring professional (family physician, psychiatrist, other clinicians) and with the patient. Accumulation: if you want to learn from your own practice over the years, you need comparable data, not impressions.

When you incorporate VR, this is especially useful. VR is a relatively new modality in clinical practice, and the field benefits from psychologists who document their results rigorously.

This article covers the most useful instruments by disorder, when to apply them, and how to integrate them into the session workflow without turning every session into paperwork.

General Principles Before Choosing Instruments

First principle: use validated instruments, not invented ones. Even with excellent clinical judgment, an ad hoc scale is not comparable. blog blog

Second principle: use instruments with a validated Spanish (or locally validated) version and published psychometric properties. A literal translation is not validation.

Third principle: apply the same instrument at the same time points. If you change the questionnaire partway through treatment, you lose comparability.

Fourth principle: do not overload the patient. Three or four pre-treatment instruments, the same ones post-treatment and at follow-up, is reasonable. A battery of fifteen scales at every session is counterproductive.

Fifth principle: complement self-report measures (questionnaires) with behavioral measures when possible (behavioral approach test, avoidance log). VR facilitates structured behavioral observation in-session.

General Anxiety: BAI and STAI

Beck Anxiety Inventory (BAI, Beck & Steer): 21 items on a 0-3 scale, measuring anxious symptomatology over the past week with an emphasis on the somatic component. Total score 0-63, with indicative cutoffs (0-7 minimal, 8-15 mild, 16-25 moderate, 26-63 severe). Validated Spanish version available (Sanz et al.). Administration time: 5-10 minutes. Useful as a transdiagnostic measure of anxiety for patients with a mixed presentation or as a complement to disorder-specific scales.

State-Trait Anxiety Inventory (STAI, Spielberger): two subscales of 20 items each (state anxiety vs. trait anxiety). Discriminates between momentary situational anxiety and stable anxious predisposition. Validated Spanish version available (Spielberger et al., TEA Ediciones adaptation). Useful if you want to track the stable component separately from the situational one.

Specific Phobias: FQ and FSS-III

Fear Questionnaire (FQ, Marks and Mathews 1979): 24 items on a 0-8 scale, grouped into three subscales (agoraphobia, social phobia, blood/injury phobia) plus global symptoms. Historical standard in the phobia literature. Administration time: 5 minutes.

Fear Survey Schedule III (Wolpe & Lang, FSS-III): 108 items assessing subjective fear of diverse stimuli on a 1-5 scale. Useful as a broad screening tool when the patient presents multiple phobias or when you want to map the stimulus hierarchy. Administration time: 15-20 minutes.

Disorder-specific: for very narrowly defined phobias, dedicated scales exist (Fear of Spiders Questionnaire, Acrophobia Questionnaire, Dental Anxiety Scale). If you frequently treat one type of phobia, it is worth having the specific scale in addition to the FQ.

Social Anxiety: LSAS-SR

Liebowitz Social Anxiety Scale, Self-Report (LSAS-SR): 24 items rated on two scales (fear 0-3, avoidance 0-3), grouping social interaction situations (12 items) and performance situations (12 items). Total score 0-144. Indicative cutoffs: <30 non-clinical social anxiety, 30-60 mild, 60-90 moderate, 90-120 severe, >120 very severe.

Validated Spanish version available (Bobes et al.). Administration time: 10-15 minutes. It is the international standard for assessing progress in social anxiety disorder and is routinely published as the primary outcome measure in clinical trials for the disorder.

PTSD: IES-R and PCL-5

Impact of Event Scale-Revised (IES-R, Weiss and Marmar): 22 items on a 0-4 scale, measuring three subscales (intrusion, avoidance, hyperarousal) referenced to a specific stressful event. Validated Spanish version available (Báguena et al.). Useful as a screening and progress measure, although it does not diagnose PTSD on its own.

PTSD Checklist for DSM-5 (PCL-5): 20 items aligned with the updated DSM-5 criteria, 0-4 scale. Total score 0-80, with an indicative clinical cutoff of 31-33 points depending on the population. Validated Spanish version available across multiple populations (Blevins et al., Spanish adaptations). It is the current standard scale for PTSD in the clinical literature, aligned with the fifth edition of the DSM.

For VRET in PTSD, we recommend using PCL-5 as the primary measure for its DSM-5 diagnostic alignment and complementing it with IES-R if you want historical traceability with cohorts that have used it.

OCD: Y-BOCS

Yale-Brown Obsessive Compulsive Scale (Y-BOCS, Goodman et al.): a 10-item semi-structured interview assessing obsessions (5 items) and compulsions (5 items) on a 0-4 scale. Total score 0-40. Indicative cutoffs: 0-7 subclinical, 8-15 mild, 16-23 moderate, 24-31 severe, 32-40 very severe.

Validated Spanish version available. It is administered as a structured clinical interview (15-30 minutes), and a faster self-report version exists (Y-BOCS-SR) with somewhat weaker psychometric properties.

International standard for OCD. If you treat OCD with VRET, this is the primary scale to document pre- and post-treatment.

SUDS: The Daily In-Session Tool

Subjective Units of Distress Scale (SUDS, Wolpe 1969): a 0-100 scale on which the patient reports their subjective level of distress at a specific moment. 0 = no distress at all, 100 = the greatest distress imaginable.

SUDS is not a validated scale in the strict psychometric sense (it has no normative validation because it is inherently subjective), but it is the standard field instrument in exposure work. It is used within-session, every few minutes, to track the dynamic evolution of anxiety during exposure.

For VRET, SUDS is the primary within-session tracking measure. Document baseline SUDS before entering the scenario, peak SUDS during exposure, and end-of-session SUDS. The clinical pattern of success is a progressive decrease in peak SUDS from session to session, indicating habituation.

In VRET (the product) you can log SUDS directly in the clinical dashboard during the session, which avoids paper and makes graphical traceability easier.

Virtual Presence: IPQ

Igroup Presence Questionnaire (IPQ, Schubert et al. 2001): 14 items on a 0-6 scale assessing the patient’s experience of presence in the virtual environment. Three subscales: spatial presence (feeling physically present in the environment), involvement (attention focused on the environment), and experienced realism (subjective plausibility of the environment).

Administering it post-session, once per patient at the start of treatment, is informative for identifying whether the patient is experiencing enough presence for the exposure to be effective. Patients with very low presence may not be benefiting from the modality, and it is worth considering adaptations or, where appropriate, an in vivo modality.

A validated Spanish version and several short adaptations exist. It is not a scale you need to apply repeatedly; once or twice at the start is enough.

Recommended Assessment Protocol

Pre-treatment assessment (first session): structured or semi-structured clinical interview, the scale specific to the primary disorder (LSAS-SR, FQ, PCL-5, Y-BOCS, as applicable), BAI as a general anxiety measure, and two open-ended questions about the patient’s expectations and goals.

Within-session assessment: baseline, peak, and end-of-session SUDS at every session. IPQ after the first and third sessions.

Post-treatment assessment (last session): repeat the specific scale and the BAI, plus a closing interview with qualitative assessment.

Follow-up: 3 months, 6 months, and 12 months post-treatment. Same scales, ideally by mail or a brief session. The 12-month follow-up is the most valuable indicator of the durability of the effects.

Documentation: a patient chart with scores at each time point, a simple chart of peak SUDS progress and of the primary scale. If your clinical software (VRET or another) allows digital logging, that is better than paper.

Communicating Results to the Patient

Sharing the scores with the patient at the end of treatment is useful clinical practice. It reinforces the sense of progress, validates the therapeutic effort, and lets the patient understand their progress objectively.

A closing conversation might include: "When we started, your LSAS-SR was 92, which indicates severe social anxiety. After 12 sessions, it is at 38, which is in the mild anxiety range. The change you notice in your day-to-day life is consistent with that objective measurement."

Pairing this with the peak-SUDS-by-session chart is especially powerful: the patient sees the habituation curve with their own eyes.

Communicating Results to the Referring Professional

If your patient was referred by a family physician, psychiatrist, or other professional, a closing report with objective data strengthens the clinical relationship and positions your practice.

A brief closing report includes: reason for referral, intervention provided (VRET, modality, number of sessions), instruments applied with pre- and post-scores, clinical assessment of current status, follow-up recommendations, discharge or a new referral if applicable.

This kind of communication, done regularly, builds a sustained referral pipeline. Professionals who receive well-written, objective reports refer more.

Accumulating Data for Your Own Clinical Improvement

Systematically documenting results over two or three years gives you your own caseload with which you can answer questions about your own practice that the literature does not answer.

Some questions that documentation answers: what effect size do I achieve for each disorder with VRET in my practice? Are there patient profiles that respond better or worse? How many sessions do I need on average to reach clinical response? How does my 12-month durability compare with the literature?

This is not formal research (you do not need ethics approval, specific consent, or publication). It is quality improvement for your own clinical practice, backed by objective data.

A Note on VRET and Clinical Records

The VRET product includes session logging with fields for baseline, peak, and end SUDS, behavioral markers recorded by the clinician during the session, notes, and PDF export. It is not a substitute for your validated scales (which you administer on paper or in your own system), but it makes the VR component of treatment easier to track.

This article is for informational purposes for psychology professionals. It is not clinical advice for any individual case and does not replace the judgment of the licensed psychologist in charge. VRET is professional clinical-support software, not a CE-marked medical device.